Effects of oral colchicine administration as first-line adjunct therapy in myopericarditis

Duran, Mustafa; Alsancak, Yakup; Zıyrek, Murat

doi:10.1007/s00059-021-05040-3

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, this observational study is the largest study evaluating the use of colchicine in patients with myopericarditis. Two previous smaller retrospective observational studies with, respectively, 27 cases 10 and 33 cases 11 reported the successful use of colchicine in the acute phase of the disease without reporting detailed outcomes on recurrences.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of colchicine for the treatment of myopericarditis

Collini,

De Martino,

Andreis

et al. 2024

Heart

View full text Add to dashboard Cite

ObjectiveClinical trials have evaluated the efficacy and safety of colchicine only in simple pericarditis, excluding cases of concomitant myocarditis. The aim of this paper is to evaluate the efficacy and safety of colchicine for the treatment of the first attack of acute pericarditis with concomitant myocardial involvement.MethodsDouble-centre retrospective cohort study analysing consecutive patients admitted for first attack of pericarditis with myocarditis and treated with or without colchicine. The primary efficacy end point was the time to the first recurrence. Propensity score matching was used to generate two groups of patients with similar baseline characteristics. Colchicine-associated side effects were analysed as safety end-point.ResultsA total of 175 patients (mean age 46.2±20.1 years, 25.1% females, 88.6% with idiopathic/viral aetiology) were included. Seventy-nine (45.1%) patients were treated with colchicine. After a median follow-up of 25.3 (IQR 8.3–45.6) months, 58 (33.1%) patients had recurrences. The propensity score generated two groups of 73 patients with similar baseline characteristics but the use of colchicine. Patients treated with colchicine had a lower incidence of recurrences (respectively, 19.2% vs 43.8%; p=0.001) and a longer event-free survival (p=0.005). In multivariable analysis, women (HR 1.97, 95% CI 1.04 to 3.73; p=0.037) and corticosteroid use (HR 2.27, 95% CI 1.15 to 4.47; p=0.018) were independent risk factors for recurrences. Colchicine-associated side effects were mild and occurred in 3 (1.7%) patients.ConclusionIn patients with first attack of pericarditis associated with myocardial involvement, colchicine was safe and efficacious for the reduction of recurrences.

show abstract

Section: Discussionmentioning

confidence: 99%